Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1928 1
1946 7
1947 1
1948 2
1950 1
1951 1
1952 5
1954 1
1955 5
1956 1
1957 2
1958 1
1959 2
1960 2
1962 1
1963 1
1964 1
1965 1
1966 1
1967 2
1969 3
1974 1
1975 2
1976 3
1978 3
1979 1
1982 1
1983 1
1984 1
1985 3
1986 3
1987 2
1989 2
1991 2
1993 2
1994 1
1995 1
1996 1
1997 3
1999 5
2000 2
2001 4
2002 5
2003 1
2004 2
2005 3
2006 3
2007 3
2008 2
2011 3
2012 2
2013 1
2014 1
2016 1
2019 2
2020 4
2021 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Results by year

Filters applied: . Clear all
Page 1
Development of a novel Ara h 2 hypoallergen with no IgE binding or anaphylactogenic activity.
Tscheppe A, Palmberger D, van Rijt L, Kalic T, Mayr V, Palladino C, Kitzmüller C, Hemmer W, Hafner C, Bublin M, van Ree R, Grabherr R, Radauer C, Breiteneder H. Tscheppe A, et al. J Allergy Clin Immunol. 2020 Jan;145(1):229-238. doi: 10.1016/j.jaci.2019.08.036. Epub 2019 Sep 13. J Allergy Clin Immunol. 2020. PMID: 31525384 Free PMC article. Clinical Trial.
Basophil activation and T-cell proliferation were tested with blood samples from selected patients. Anaphylactogenic potency was tested by using intraperitoneal challenge of mice sensitized intragastrically to peanut extract. ...CONCLUSIONS: By removing conformational and …
Basophil activation and T-cell proliferation were tested with blood samples from selected patients. Anaphylactogenic potency was test …
Soybean: anaphylactogenic properties.
RATNER B, CRAWFORD LV. RATNER B, et al. Ann Allergy. 1955 May-Jun;13(3):289-95. Ann Allergy. 1955. PMID: 14377223 No abstract available.
Suppressive effect of non-anaphylactogenic anti-IgE antibody on the development of dextran sulfate sodium-induced colitis.
Kang OH, Kim DK, Choi YA, Park HJ, Tae J, Kang CS, Choi SC, Nah YH, Lee HK, Lee YM. Kang OH, et al. Int J Mol Med. 2006 Nov;18(5):893-9. Int J Mol Med. 2006. PMID: 17016619
The non-anaphylactogenic anti-IgE antibody was subcutaneously injected on day 0 of DSS treatment. ...Thus, these results indicate that the IgE response played an important role in the clinical signs and the expression of inflammatory mediators in a colitis model caused by …
The non-anaphylactogenic anti-IgE antibody was subcutaneously injected on day 0 of DSS treatment. ...Thus, these results indicate tha …
Immunotherapy approach to allergic disease.
Fick RB Jr, Fox JA, Jardieu PM. Fick RB Jr, et al. Immunopharmacology. 2000 Jul 25;48(3):307-10. doi: 10.1016/s0162-3109(00)00229-0. Immunopharmacology. 2000. PMID: 10960673 Review.
This anti-IgE antibody binds at the same epitope site of IgE that binds to FcvarepsilonRI and is thus non-anaphylactogenic. By binding to IgE and removing it via immune complex formation, the pool of IgE available to interact with mast cells and basophils is thereby reduce …
This anti-IgE antibody binds at the same epitope site of IgE that binds to FcvarepsilonRI and is thus non-anaphylactogenic. By bindin …
Therapeutic potential of anti-IgE antibodies.
Heusser C, Jardieu P. Heusser C, et al. Curr Opin Immunol. 1997 Dec;9(6):805-13. doi: 10.1016/s0952-7915(97)80182-3. Curr Opin Immunol. 1997. PMID: 9492982 Review.
Thus interruption of the allergic cascade at the IgE antibody level with non-anaphylactogenic anti-IgE antibodies is effective and represents an attractive intervention for the treatment of allergic diseases....
Thus interruption of the allergic cascade at the IgE antibody level with non-anaphylactogenic anti-IgE antibodies is effective and re …
Transcriptional frameshifts contribute to protein allergenicity.
Thouvenot B, Roitel O, Tomasina J, Hilselberger B, Richard C, Jacquenet S, Codreanu-Morel F, Morisset M, Kanny G, Beaudouin E, Delebarre-Sauvage C, Olivry T, Favrot C, Bihain BE. Thouvenot B, et al. J Clin Invest. 2020 Oct 1;130(10):5477-5492. doi: 10.1172/JCI126275. J Clin Invest. 2020. PMID: 32634131 Free PMC article.
In mice, recombinant TI variants of the peanut allergen Ara h 2, but not the canonical allergen itself, induced, without adjuvant, the production of anaphylactogenic specific IgE (sIgE), binding to linear epitopes on both canonical and TI segments of the TI variants. ...
In mice, recombinant TI variants of the peanut allergen Ara h 2, but not the canonical allergen itself, induced, without adjuvant, the produ …
Molecular aspects of allergy.
Miescher SM, Vogel M. Miescher SM, et al. Mol Aspects Med. 2002 Dec;23(6):413-62. doi: 10.1016/s0098-2997(02)00009-2. Mol Aspects Med. 2002. PMID: 12385747 Review.
The most promising therapeutic approaches are aimed at inhibiting the IgE-Fc epsilon RI interaction with the use of non-anaphylactogenic anti-IgE or anti-Fc epsilon RIalpha autoantibodies. Clinical trials in humans using an humanised anti-IgE antibody showed that this anti …
The most promising therapeutic approaches are aimed at inhibiting the IgE-Fc epsilon RI interaction with the use of non-anaphylactogenic
119 results